StockData

IDEXX Laboratories vs Neogen

IDXX and NEOG side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IDXX and NEOG compare

IDEXX Laboratories is the larger company, worth 23 times as much as Neogen ($54.4B against $2.4B).

IDEXX Laboratories grew revenue faster over the last twelve months (12.8% versus −0.33% for Neogen).

IDEXX Laboratories keeps more of each dollar of sales as profit, with a net margin of 25.0% compared with −6.3% at Neogen.

IDEXX Laboratories scores higher on the StockData Score (19 against 7 for Neogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIDXXNEOG
Size and price
Market cap$54.4B$2.4B
Share price$690.24$10.90
Change, 1 year0.04%70.6%
Change, 5 years13.6%−73.5%
Beta (5Y)0.340.86
Employees11K2,636
StockData Score
Total score19 (better)7
Valuation score2 (better)1
Growth score5 (better)2
Performance score6 (better)3
Health score6 (better)1
Dividend score00
Valuation
P/E48.5×–
P/S11.9×2.7× (better)
P/B33.7×1.1× (better)
EV/EBITDA33.9× (better)34.5×
P/FCF43.4× (better)47.8×
PEG2.75–
FCF yield2.3% (better)2.1%
Fair value$509.32$7.32
Margin of safety−35.5% (better)−48.8%
Growth
Revenue growth (TTM)12.8% (better)−0.33%
Revenue growth, 5Y average9.7%13.2% (better)
Net income growth (TTM)15.6%–
EPS growth (TTM)18.4%–
EPS growth, 5Y average14.3%–
Profitability
Gross margin62.4% (better)47.4%
Operating margin32.0% (better)−0.83%
Net margin25.0% (better)−6.3%
FCF margin27.5% (better)5.6%
Return on equity74.2% (better)−2.7%
Return on invested capital63.3% (better)−0.17%
Financial health
Debt / equity0.28 (better)0.74
Net debt / EBITDA0.16 (better)12.69
Interest coverage38.6×–
Current ratio1.173.90 (better)
Altman Z-score23.48 (better)1.36
Piotroski F-score8 (better)6
Dividends and buybacks
Buyback yield2.2%–
Shareholder yield2.2% (better)0.00%
Ownership
Held by institutions94.5%109%
Held by insiders0.29%0.60%
Insider net buying, 12 months−$58.4M−$102K (better)
Superinvestors holding3–
Short interest, % of float3.0%5.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.